![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting ... ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting. Show more
SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- In collaboration with leading medical researchers from around the world, ResMed (NYSE: RMD, ASX: RMD) presented 13 new clinical studies at SLEEP...
Among 26 ResMed-supported abstracts, these were the highlights: New findings show positive airway pressure (PAP) therapy reduced risks of death and hospitalization for patients with obstructive...
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- When: May 17–22, 2024Where: San Diego Convention Center (SDCC) | 111 Harbor Dr. San Diego, CA 92101 Marriott...
BLOOMINGTON, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- MatrixCare, a leading global technology provider in post-acute care, has partnered with Health Gorilla, the nation’s only dual-designated...
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will...
Year-over-year revenue grows 7%, operating profit up 25%, non-GAAP operating profit up 23%Operating cash flows of $402 million Note: A webcast of ResMed’s conference call will be available at 4:30...
SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -26.955 | -12.7785152176 | 210.94 | 214.97 | 179.42 | 2541561 | 192.71616352 | CS |
4 | -21.175 | -10.321212712 | 205.16 | 214.97 | 179.42 | 1297082 | 202.64169561 | CS |
12 | -2.005 | -1.07801494704 | 185.99 | 222.96 | 172.19 | 1132990 | 201.79244571 | CS |
26 | 12.585 | 7.34247374562 | 171.4 | 222.96 | 164.1225 | 1043994 | 192.98369851 | CS |
52 | -32.245 | -14.9123618369 | 216.23 | 229.97 | 132.24 | 1189063 | 174.91183231 | CS |
156 | -62.845 | -25.4608434955 | 246.83 | 301.34 | 132.24 | 769583 | 202.86821609 | CS |
260 | 63.925 | 53.2442112277 | 120.06 | 301.34 | 108.85 | 704921 | 192.46475439 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions